Kissei's antidiabetic mitiglinide approved in China
26 November 2009
Ian Haydock
Please Login to read the full article.
26 November 2009
Ian Haydock
ian.haydock@informa.com
Kissei Pharmaceutical has received regulatory approval for its antidiabetic Glufast (mitiglinide) in China, where the rapid-acting insulin secretagogue will be launched and marketed by fellow Japanese company Eisai.
The product was filed for import approval in the country in January 2008,...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Takeda's diabetes pipeline moves forward as first-in-class GPR40 agonist enters Phase III
- Sitagliptin and alogliptin go head-to-head in Japan
- Jury still out on benefits of glucose lowering treatments, says German HTA body
- Boehringer, Lilly win US approval of Tradjenta in Type II diabetes
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
